Patrick Campbell

Results of a first-in-man trial suggests a non-invasive ultrasound therapy improved cardiovascular health in patients with severe calcific aortic stenosis (CAS).

A new systematic review and meta-analysis is shedding light on the impact gestational hypertension can have on future risk of cardiovascular diseases.

An analysis of data from a trio of phase 3 trials suggest use of the novel osteoporotic treatment could increase risk of heart attack by 18%.

Results of an exploratory analysis of the phase 3 MARINER study indicates post-discharge prophylaxis with rivaroxaban (Xarelto) could reduce the risk of both fatal and major thromboembolic events in medically ill patients.

An analysis of the MARINER trial is diving deeper into the impact of post-discharge prophylaxis with rivaroxaban in patients with more severe renal impairment.

New research suggests the microbiome from the tongue coating of patients with heart failure contains unique differences to those of healthy patients.

While often referred to as "Good cholesterol" new research suggests HDL measurements do little for predicting risk of heart attack in Black patients

A new study found newly diagnosed type 2 diabetics who develop heart failure had the highest risk of death versus patients with other CVDs or chronic kidney disease.

New research suggests development of heart failure is associated with the greatest risk of death among type 2 diabetics with cardiovascular conditions.

New research from ARVO 2020 suggests patients with diabetic eye disease can still experiences losses in visual acuity, even with glycemic control.

A survey of 19 patients with hereditary retinitis pigmentosa details the impact of the disease on the quality of life and daily activity of patients and caregivers.

New research suggests signs a person may be more susceptible to type 2 diabetes later in life are visible in children as young as 8 years old.

The FDA's approval of insulin lispro-aabc injection is based on the results of 2 phase 3 trials—PRONTO-T1D and PRONTO-T2D.

Crysvita received approval from the FDA for treatment of TIO in patients aged 2 years and older.

Both type 1 and type 2 diabetics now have an additional insulin option available to them in the form of insulin lispro-aabc injection (Lyumjev) 100 units/mL and 200 units/mL.

New research from Penn Medicine indicates 9.6% of heart surgery patients develop persistent opioid use post-procedure.

A nationwide analysis indicates stroke patients in rural areas were at a greater risk of mortality and less likely to receive advanced treatment than urban counterparts.

A pooled analysis of 5 PIONEER trials presented by John Buse, MD, at ADA 2020 is shedding new light on the impact of oral semaglutide based on background glucose-lowering therapy.

An analysis of data from 5 PIONEER trials is shedding new light on the impact of oral semaglutide based on background glucose-lowering therapy.

Discussing how advances in care and therapeutic agents have impacted the management of diabetes in 2020.

Results of the VERTIS-CV trial indicate ertugliflozin could reduce heart failure hospitalizations but did not demonstrate the ability to reduce MACE compared to placebo.

Discussing an analysis of retrospective claims data to examine the incidence of herpes zoster in patients with T2DM and how it impacts their diabetes.

Lead investigator of VERTIS-CV discusses results of the phase 3 trial examining ertugliflozin's impact on cardiovascular health.

An analysis of nearly 8k veterans has found use of metformin was associated with a reduction in PTSD symptoms.

Data from a phase 2 trial presented at ADA 2020 suggests ladarixin, a CXCR1/2 inhibitor, could provide benefit to patients with type 1 diabetes.

An analysis of the DECLARE-TIMI 58 trial suggests dapagliflozin use could reduce the risk of fast decline in eGFR.

Examining the results of MEX0114, a phase 2 trial evaluating the use of ladarixin in patients with new-onset type 1 diabetes.

A leader in the field diabetic care, and endocrinology as a whole, Bruce Bode, MD, offers invaluable perspective on the impact of COVID-19 on clinical practice and major trials.

Results of a new study are diving deeper into potential mediators of the effects of canagliflozin on heart failure and CV death seen in CREDENCE.

A prespecified exploratory analysis suggests the SGLT2 inhibitor reduced the rate of new-onset diabetes by nearly a third.